Potential therapeutic value of drugs inhibiting semicarbazide-sensitive amine oxidase: vascular cytoprotection in diabetes mellitus.
Semicarbazide-sensitive amine oxidase (SSAO) is a copper-containing enzyme found in large amounts in blood plasma and in vascular smooth muscle. The catalytic activity of this enzyme is elevated in diabetes mellitus and some substrates, such as aminoacetone and methylamine also occur in increased amounts in this disease. After deamination by SSAO highly angiotoxic products are formed, methylglyoxal and formaldehyde, respectively. Moreover, hydrogen peroxide is also formed as a side-product. These products arising from SSAO-catalysed reactions may partially explain late-diabetic damages in the kidneys, eyes and peripheral nerves, as well as other cardiovascular disorders. It is therefore proposed that inhibition of SSAO may decrease the formation of these cytotoxic products and therefore prevent or slow the development of late-diabetic complications.
Ekblom
J
J
Department of Medical Pharmacology, Uppsala University, Sweden.
D006631:Amine Oxidase (Copper-Containing) / Q000037:antagonists & inhibitors* / Q000097:blood; D001808:Blood Vessels / Q000187:drug effects*; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000201:enzymology*; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans
D004791:Enzyme Inhibitors; D006631:Amine Oxidase (Copper-Containing)